VERA vs. BRK-B

Last updated Apr 2, 2026

Compare and contrast key facts about Vera Therapeutics, Inc. (VERA) and Berkshire Hathaway Inc. (BRK-B).

Performance

VERA vs. BRK-B - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Vera Therapeutics, Inc. (VERA) and Berkshire Hathaway Inc. (BRK-B). The values are adjusted to include any dividend payments, if applicable.

VERA vs. BRK-B - Yearly Performance Comparison

	2026 (YTD)	2025	2024	2023	2022	2021
VERA Vera Therapeutics, Inc.	-20.02%	19.74%	174.97%	-20.52%	-27.58%	132.35%
BRK-B Berkshire Hathaway Inc.	-4.80%	10.89%	27.09%	15.46%	3.31%	2.86%

Fundamentals

Market Cap VERA : $2.60B BRK-B : $1.03T
EPS VERA : -$4.68 BRK-B : $31.03
PB Ratio VERA : 4.30 BRK-B : 1.44
Total Revenue (TTM) VERA : $0.00 BRK-B : $371.37B
Gross Profit (TTM) VERA : $0.00 BRK-B : $116.89B
EBITDA (TTM) VERA : -$315.47M BRK-B : $87.30B

Returns By Period

In the year-to-date period, VERA achieves a -20.02% return, which is significantly lower than BRK-B's -4.80% return.

VERA

• 1D: 0.67%
• 1M: 0.20%
• YTD: -20.02%
• 6M: 40.67%
• 1Y: 83.92%
• 3Y*: 73.46%
• 5Y*: —
• 10Y*: —

BRK-B

• 1D: -0.15%
• 1M: -0.35%
• YTD: -4.80%
• 6M: -3.95%
• 1Y: -10.22%
• 3Y*: 15.72%
• 5Y*: 13.13%
• 10Y*: 12.78%

*Multi-year figures are annualized to reflect compound growth (CAGR)

Return for Risk

VERA vs. BRK-B — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

VERA

VERA Risk / Return Rank: 74
VERA Sharpe Ratio Rank: 71
VERA Sortino Ratio Rank: 81
VERA Omega Ratio Rank: 78
VERA Calmar Ratio Rank: 73
VERA Martin Ratio Rank: 68

BRK-B

BRK-B Risk / Return Rank: 17
BRK-B Sharpe Ratio Rank: 16
BRK-B Sortino Ratio Rank: 16
BRK-B Omega Ratio Rank: 16
BRK-B Calmar Ratio Rank: 17
BRK-B Martin Ratio Rank: 19

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

VERA vs. BRK-B - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Vera Therapeutics, Inc. (VERA) and Berkshire Hathaway Inc. (BRK-B). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

	VERA	BRK-B	Difference
Sharpe ratio Return per unit of total volatility	0.89	-0.56	+1.45
Sortino ratio Return per unit of downside risk	2.21	-0.65	+2.86
Omega ratio Gain probability vs. loss probability	1.28	0.91	+0.37
Calmar ratio Return relative to maximum drawdown	1.72	-0.68	+2.40
Martin ratio Return relative to average drawdown	3.23	-1.16	+4.39
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month.

VERA vs. BRK-B - Sharpe Ratio Comparison

The current VERA Sharpe Ratio is 0.89, which is higher than the BRK-B Sharpe Ratio of -0.56. The chart below compares the historical Sharpe Ratios of VERA and BRK-B, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.

Sharpe Ratios by Period

	VERA	BRK-B	Difference
Sharpe Ratio (1Y) Calculated over the trailing 1-year period	0.89	-0.56	+1.45
Sharpe Ratio (5Y) Calculated over the trailing 5-year period	—	0.77	—
Sharpe Ratio (10Y) Calculated over the trailing 10-year period	—	0.66	—
Sharpe Ratio (All Time) Calculated using the full available price history	0.32	0.48	-0.16

Correlation

The correlation between VERA and BRK-B is 0.15, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.

Dividends

VERA vs. BRK-B - Dividend Comparison

Neither VERA nor BRK-B has paid dividends to shareholders.

Tickers have no history of dividend payments

Drawdowns

VERA vs. BRK-B - Drawdown Comparison

The maximum VERA drawdown since its inception was -84.89%, which is greater than BRK-B's maximum drawdown of -53.86%. Use the drawdown chart below to compare losses from any high point for VERA and BRK-B.

Drawdown Indicators

	VERA	BRK-B	Difference
Max Drawdown Largest peak-to-trough decline	-84.89%	-53.86%	-31.03%
Max Drawdown (1Y) Largest decline over 1 year	-39.83%	-14.95%	-24.88%
Max Drawdown (5Y) Largest decline over 5 years	—	-26.58%	—
Max Drawdown (10Y) Largest decline over 10 years	—	-29.57%	—
Current Drawdown Current decline from peak	-27.25%	-11.36%	-15.89%
Average Drawdown Average peak-to-trough decline	-40.29%	-11.07%	-29.22%
Ulcer Index Depth and duration of drawdowns from previous peaks	21.24%	8.72%	+12.52%

Volatility

VERA vs. BRK-B - Volatility Comparison

Vera Therapeutics, Inc. (VERA) has a higher volatility of 13.53% compared to Berkshire Hathaway Inc. (BRK-B) at 4.33%. This indicates that VERA's price experiences larger fluctuations and is considered to be riskier than BRK-B based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

Volatility by Period

	VERA	BRK-B	Difference
Volatility (1M) Calculated over the trailing 1-month period	13.53%	4.33%	+9.20%
Volatility (6M) Calculated over the trailing 6-month period	43.63%	11.14%	+32.49%
Volatility (1Y) Calculated over the trailing 1-year period	94.76%	18.30%	+76.46%
Volatility (5Y) Calculated over the trailing 5-year period, annualized	92.50%	17.20%	+75.30%
Volatility (10Y) Calculated over the trailing 10-year period, annualized	92.50%	19.45%	+73.05%

Financials